PMID- 31909763 OWN - NLM STAT- MEDLINE DCOM- 20200724 LR - 20200724 IS - 2038-1840 (Electronic) IS - 0034-1193 (Linking) VI - 110 IP - 12 DP - 2019 Dec TI - [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.]. PG - 604-614 LID - 10.1701/3278.32519 [doi] AB - BACKGROUND: The availability of subcutaneous (SC) and intravenous (EV) formulations of trastuzumab and the recent release of the biosimilar EV version (10/2018) increase the offer for the treatment of patients with breast or gastric cancer HER2 positive. In this context, it is necessary to build therapeutic scenarios form avalible data in order to estimate the potential savings for the Regional Health Service (RHS) taking into account the appropriateness of use and patient's preferences. AIM: To evaluate the available comparative evidence regarding the effectiveness and safety of the different trastuzumab formulations; to analyze the supply of trastuzumab by type of administration (EV/SC) in Lazio in 2018, identifying the most appropriate use; to hypothesize a cost-effective scenario for the Regional Health Service (SSR) in 2019. Mehods. With the working group formed by clinicians and methodologists, we analysed the evidence of efficacy and safety available to date for the different formulations of trastuzumab, also taking into account the recent availability of biosimilars and with particular regard to the phenomenon of the potential switch between different therapeutic options. In addition, for the year 2019 the available economic impact assessments were also simulated with data from the Lazio Region. Through the datas from direct pharmaceutical products, the transtuzumab cycles supplied in 2018 were identified separately for the available formulations (EV/SC). For each cycle of therapy, starting from the date of delivery, the possible presence of a concomitant treatment (+/- 2 days) was investigated, tracing the type and method of administration. The treatments (concomitant with trastuzumab) were identified for which there were conflicting modes of administration. In addition, the supply of SC per dispensing structure was evaluated and, on the basis of this information, a scenario of use was hypothesized that takes into account costs and plausible consumption. RESULTS: A review of the literature summarized the available evidence on the efficacy and safety of the use of trastuzumab in the recorded therapeutic indications. The review was discussed with the working group and used to reproduce, at regional level, the estimates of the economic impact of the different therapeutic choices possible with trastuzumab. As regards the data on the use of trastuzumab, in the Lazio Region in 2018, 22,214 treatment cycles were observed (at a cost of 33 million euro) for 2,407 patients; new users accounted for 52.2%. 46.8% of the cycles were administered via SC; the use of the biosimilar was observed from October onwards and involved 143 cycles (0.6%). In 68.4% of the cycles trastuzumab was administered in monotherapy; among the therapies associated with trastuzumab, the most frequent was pertuzumab (n=4,258, 19.2% of the total cycles), followed by paclitaxel (n=1,364, 6.1% of the total cycles). Among the cycles of trastuzumab in concomitant therapy (N=7,022), 17.3% was administered via SC despite the presence of other drugs administered via EV. The prescriptive pattern of trastuzumab was heterogeneous for the different delivery structures. The SC administration presents a variability in the supply from 26% to 70% (interquartile range) and does not seem to be related to the type and volume of activity of the hospital. If the biosimilar EV is expected to account for 55% of consumption by 2019, thus reducing the use of the EV originator to 10% and the SC originator to 35%, savings of more than euro7 million. CONCLUSIONS: Through the use data of the different formulations available for trastuzumab and taking into account the prescriptive appropriateness (and patient preferences), it has been possible to identify a SSR scenario of economic convenience due to the greater use of the biosimilar. FAU - Belleudi, Valeria AU - Belleudi V AD - Dipartimento di Epidemiologia, Servizio Sanitario Regionale del Lazio, Roma. FAU - Rosa, Alessandro Cesare AU - Rosa AC AD - Dipartimento di Epidemiologia, Servizio Sanitario Regionale del Lazio, Roma. FAU - Musicco, Felice AU - Musicco F AD - IFO - Istituti Fisioterapici Ospitalieri, Roma. FAU - Marchetti, Paolo AU - Marchetti P AD - Oncologia Medica B, Policlinico Umberto I, Sapienza Universita di Roma. FAU - Martini, Nello AU - Martini N AD - Fondazione ReS - Ricerca e Salute Roma. FAU - Andriani, Alessandro AU - Andriani A AD - UOC Ematologia, Frosinone. FAU - Calamia, Teresa AU - Calamia T AD - Area del Farmaco, Asl Rm1, Roma. FAU - Addis, Antonio AU - Addis A AD - Dipartimento di Epidemiologia, Servizio Sanitario Regionale del Lazio, Roma. LA - ita PT - Comparative Study PT - Journal Article TT - Utilizzo appropriato del trastuzumab nel Lazio: scenari terapeutici e stima del possibile risparmio per il Servizio Sanitario Regionale. PL - Italy TA - Recenti Prog Med JT - Recenti progressi in medicina JID - 0401271 RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (Biosimilar Pharmaceuticals) RN - P188ANX8CK (Trastuzumab) SB - IM MH - Administration, Intravenous MH - Antineoplastic Agents, Immunological/*administration & dosage/adverse effects/economics MH - Biosimilar Pharmaceuticals/*administration & dosage/adverse effects/economics MH - Breast Neoplasms/drug therapy/economics MH - Cost-Benefit Analysis MH - Female MH - Humans MH - Injections, Subcutaneous MH - Italy MH - Stomach Neoplasms/drug therapy/economics MH - Trastuzumab/*administration & dosage/adverse effects/economics EDAT- 2020/01/08 06:00 MHDA- 2020/07/25 06:00 CRDT- 2020/01/08 06:00 PHST- 2020/01/08 06:00 [entrez] PHST- 2020/01/08 06:00 [pubmed] PHST- 2020/07/25 06:00 [medline] AID - 10.1701/3278.32519 [doi] PST - ppublish SO - Recenti Prog Med. 2019 Dec;110(12):604-614. doi: 10.1701/3278.32519.